MA25284A1 - Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose. - Google Patents

Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.

Info

Publication number
MA25284A1
MA25284A1 MA25719A MA25719A MA25284A1 MA 25284 A1 MA25284 A1 MA 25284A1 MA 25719 A MA25719 A MA 25719A MA 25719 A MA25719 A MA 25719A MA 25284 A1 MA25284 A1 MA 25284A1
Authority
MA
Morocco
Prior art keywords
carnitine
glucose
improves
antioxidant composition
including acetylene
Prior art date
Application number
MA25719A
Other languages
English (en)
French (fr)
Inventor
Cavazza Claudio
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11406116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA25284(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of MA25284A1 publication Critical patent/MA25284A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
MA25719A 1998-09-01 1999-08-06 Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose. MA25284A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998RM000566A IT1302307B1 (it) 1998-09-01 1998-09-01 Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil

Publications (1)

Publication Number Publication Date
MA25284A1 true MA25284A1 (fr) 2001-12-31

Family

ID=11406116

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25719A MA25284A1 (fr) 1998-09-01 1999-08-06 Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.

Country Status (28)

Country Link
US (1) US6365622B1 (enExample)
EP (1) EP1112005B2 (enExample)
JP (1) JP4361215B2 (enExample)
KR (1) KR20010079699A (enExample)
CN (1) CN1315835A (enExample)
AR (1) AR022076A1 (enExample)
AT (1) ATE228312T1 (enExample)
AU (1) AU773424B2 (enExample)
BR (1) BR9913288A (enExample)
CA (1) CA2341973C (enExample)
CZ (1) CZ2001541A3 (enExample)
DE (1) DE69904208T3 (enExample)
DK (1) DK1112005T4 (enExample)
EE (1) EE200100113A (enExample)
ES (1) ES2188214T5 (enExample)
HK (1) HK1039730A1 (enExample)
HU (1) HU229165B1 (enExample)
IL (1) IL141435A0 (enExample)
IS (1) IS5850A (enExample)
IT (1) IT1302307B1 (enExample)
MA (1) MA25284A1 (enExample)
NO (1) NO20010954L (enExample)
PL (1) PL212737B1 (enExample)
PT (1) PT1112005E (enExample)
SK (1) SK2632001A3 (enExample)
TN (1) TNSN99163A1 (enExample)
TR (1) TR200100610T2 (enExample)
WO (1) WO2000011968A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479069B1 (en) 1999-09-23 2002-11-12 Juvenon, Inc. Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
US6335361B1 (en) * 1999-11-03 2002-01-01 Juvenon Inc. Method of treating benign forgetfulness
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
DE10036797A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Verwendung von Kombinationen mit einem Gehalt an Carnitinen
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US20020076470A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
JP2010142237A (ja) * 2000-10-31 2010-07-01 Colgate Palmolive Co 組成物及び方法
AU2002232616A1 (en) * 2000-10-31 2002-06-11 Colgate-Palmolive Company Compositions containing an antioxidant such as alpha lipoic acid, carnitine, vitamin C or vitamin E for preventing or inhibiting loss of cognitive function
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
EA006429B1 (ru) * 2001-03-09 2005-12-29 Сосьете Де Продюи Нестле С.А. Композиция для предупреждения или восстановления возрастных функциональных дефицитов у млекопитающих и способ ее применения
SE0102380D0 (sv) * 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
US6923960B2 (en) 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
WO2003053336A2 (en) * 2001-12-19 2003-07-03 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
WO2003072052A2 (en) * 2002-02-22 2003-09-04 Albany College Of Pharmacy Methods and compounds useful in inhibiting oxidative and/or free radical damage and in the treatment and prevention of disease
US20040132821A1 (en) * 2002-10-11 2004-07-08 Roberto Crea Therapeutic combination of carnitine and antioxidant polyphenols
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
DE10258239A1 (de) * 2002-12-13 2004-06-24 Degussa Ag Formulierung enthaltend alpha-Liponsäure(-Derivate) als alleinigen Wirkstoff bei nichtchronischen alkoholinduzierten Intoxikationen
US20040265345A1 (en) * 2003-06-30 2004-12-30 Perricone Nicholas V. Treatment of skin damage using acetyl carnitine and lipoic acid
US7999003B2 (en) 2003-08-26 2011-08-16 Mannatech, Incorporated Antioxidant compositions and methods thereto
US20050214413A1 (en) * 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
EP1706146B1 (en) 2003-12-31 2013-08-21 K-Pax Pharmaceuticals, Inc. Nutrient compositions and use thereof for enhanced effectiveness of the immune system
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
CA2588708C (en) * 2004-11-24 2014-05-27 Hill's Pet Nutrition, Inc. Use of lipoic acid to improve immune response by increased natural killer cell activity
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
DK1817058T3 (en) * 2004-11-24 2015-12-07 Hills Pet Nutrition Inc COMPOSITION FOR USE FOR IMPROVING THE hepatic clearance xenobiotics WITH AN ANIMAL
AU2005322015B2 (en) 2004-12-29 2010-02-25 Hill's Pet Nutrition, Inc. Methods for inhibiting a decline in learning and/or memory in animals
US8148325B2 (en) * 2004-12-30 2012-04-03 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8252742B2 (en) 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニSigma−Tau Industrie Farmaceutiche Riunite Societa Per Azioni 有痛性末梢糖尿病性神経障害の予防のためのアセチルl−カルニチン
JP5284087B2 (ja) 2005-07-14 2013-09-11 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物の生命を延長するための方法
CA2664982C (en) * 2006-02-23 2015-12-29 Nou-Life Sciences, Inc. Cleavable carnitine compound
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
CN101057857B (zh) * 2006-04-21 2011-05-18 中国科学院上海生命科学研究院 一种预防与改善帕金森氏症的组合物及其制法
KR100811110B1 (ko) * 2007-02-21 2008-03-06 주식회사 디피아이 솔루션스 수분산성 α-리포산 캡슐 조성물을 함유하는 어류의 면역력증강용 사료첨가제 및 그 사용방법.
US20080226696A1 (en) * 2007-03-15 2008-09-18 Ben Treadwell Methods of improving learning abilities of aged companion animals
WO2009020317A2 (en) * 2007-08-06 2009-02-12 Biogenics, Inc. Stabilized antioxidant particles, composition comprising the same and method for preparing the same
KR20090014568A (ko) * 2007-08-06 2009-02-11 (주)바이오제닉스 코팅된 알파리포산 입자, 이를 포함하는 조성물 및 그 제조방법
US7943163B2 (en) 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
KR100903549B1 (ko) * 2008-07-29 2009-06-23 주식회사 카이로제닉스 균질한 결정성의 아세틸-l-카르니틴과 티옥트산 칼륨염의 복합염, 이의 제조방법 및 이를 포함하는 약학적 조성물
BRPI0921679A2 (pt) * 2008-11-11 2016-02-16 Sigma Tau Ind Farmaceuti composto útil para tratar celulite
EP2389931A1 (en) * 2010-05-21 2011-11-30 Raw Materials Internatinal LLC Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
PT2787968T (pt) 2011-12-07 2020-06-16 Allergan Inc Administração eficaz de lípidos ao filme lacrimal humano utilizando um sistema de emulsão sensível ao sal
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US20140371280A1 (en) * 2013-03-15 2014-12-18 Shinichi Okuyama Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial ATP production, and through induction of neuronal regeneration
US20190290609A1 (en) * 2014-03-19 2019-09-26 Epitech Group S.P.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
CA2965671A1 (en) 2014-10-24 2016-04-28 Robert Shorr Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
AU2015353701B2 (en) 2014-11-25 2021-03-25 Allergan, Inc. Stabilized omega-3 ophthalmic compositions
PL3277273T3 (pl) 2015-03-31 2020-11-02 Kolinpharma S.P.A. Kompozycja do leczenia neuropatii i/lub bólu neuropatycznego
CN107922922A (zh) * 2015-08-24 2018-04-17 维特罗利夫瑞典股份公司 培养基
US11998554B2 (en) * 2018-09-10 2024-06-04 URIACH ITALY S.r.l. Composition comprising lipoic acid and vitamin D for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies
CN111467385B (zh) * 2019-01-24 2022-05-17 深圳市华大农业应用研究院 组合物在预防或治疗神经退行性疾病中的用途
DK3773012T3 (da) * 2019-04-18 2021-09-13 Simo Rasi Sammensætning til anvendelse ved forebyggelse eller reduktion af oxidativt stress og neurodegenerative sygdomme
WO2022215085A1 (en) * 2021-04-06 2022-10-13 Celagenex Research (India) Pvt. Ltd. A synergistic composition for potentiating stabilized atp
CN112999220B (zh) * 2021-04-07 2022-12-13 中国人民解放军南部战区总医院 α-硫辛酸在作为和/或制备金属β-内酰胺酶抑制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
AU6482596A (en) 1995-07-03 1997-02-05 Wilson T. Crandall Transdermal and oral treatment of androgenic alopecia
IT1283967B1 (it) 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
CA2280093A1 (en) * 1997-02-04 1998-08-06 John V. Kosbab Compositions and methods for prevention and treatment of vascular degenerative diseases
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5916912A (en) 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress

Also Published As

Publication number Publication date
CN1315835A (zh) 2001-10-03
CZ2001541A3 (cs) 2001-09-12
AR022076A1 (es) 2002-09-04
IS5850A (is) 2001-02-16
DK1112005T4 (da) 2010-06-14
BR9913288A (pt) 2001-05-22
DK1112005T3 (da) 2002-12-30
JP2002523435A (ja) 2002-07-30
ATE228312T1 (de) 2002-12-15
EP1112005A1 (en) 2001-07-04
ITRM980566A0 (it) 1998-09-01
WO2000011968A8 (en) 2000-05-11
AU5387199A (en) 2000-03-21
WO2000011968A1 (en) 2000-03-09
HUP0102909A2 (hu) 2002-03-28
CA2341973C (en) 2009-05-12
EP1112005B2 (en) 2010-03-24
ES2188214T5 (es) 2010-06-08
CA2341973A1 (en) 2000-03-09
PL212737B1 (pl) 2012-11-30
AU773424B2 (en) 2004-05-27
EE200100113A (et) 2002-06-17
KR20010079699A (ko) 2001-08-22
PL346318A1 (en) 2002-01-28
HK1039730A1 (zh) 2002-05-10
PT1112005E (pt) 2003-03-31
DE69904208D1 (de) 2003-01-09
DE69904208T2 (de) 2003-08-28
US6365622B1 (en) 2002-04-02
IL141435A0 (en) 2002-03-10
ITRM980566A1 (it) 2000-03-01
EP1112005B1 (en) 2002-11-27
NO20010954D0 (no) 2001-02-26
DE69904208T3 (de) 2010-09-30
TR200100610T2 (tr) 2001-07-23
HU229165B1 (en) 2013-09-30
ES2188214T3 (es) 2003-06-16
TNSN99163A1 (fr) 2005-11-10
JP4361215B2 (ja) 2009-11-11
IT1302307B1 (it) 2000-09-05
SK2632001A3 (en) 2001-08-06
NO20010954L (no) 2001-04-25
HUP0102909A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
TNSN99132A1 (fr) Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause
TNSN96107A1 (fr) Benzylaminopiperidines substitues et compositions pharmaceutiques les contenant
FR2448348A1 (fr) Composition pharmaceutique comprenant une acyl-carnitine pour le traitement du metabolisme cerebral perturbe
TNSN99253A1 (fr) Composes chimiques nouveaux modulateurs de ccr5, et compositions pharmaceutiques les contenant.
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
KR970020098A (ko) 항스트레스 조성물
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
BE901737A (fr) Composition pharmaceutique pour le traitement de l'ischemie myocardique aigue.
TNSN98112A1 (fr) Composes dipeptidiques
BE901994A (fr) Comprimes de principes actifs pharmaceutiques a delitement rapide, stables au stockage.
CA2331395A1 (en) Fatty acid analogues for the treatment of diabetes
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN99135A1 (fr) Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression
TNSN00231A1 (fr) Forme cristalline de 4-carboxyamino-2-substitue-1,2,3,4- tetrahydroquinoleine, et compositions la contenant
DE69526353D1 (de) Immunologische aktivität der rhamnolipide
TNSN98127A1 (fr) Derives d'azetidinylpropylpiperidine , procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN00077A1 (fr) Une composition comportant un carnitine et du glutathione, utilisable pour augmenter l'absorption du glutathione et synergiser ces effets
CA2147807A1 (fr) Composes bicycliques-aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2147808A1 (fr) Composes bi-aromatiques acetylenes a groupement adamantyle, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2191790A1 (fr) Composes biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
BE900564A (fr) Composition pharmaceutique pour le traitement d'arteriopathies peripheriques.
DE69802113D1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
TNSN99013A1 (fr) Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
KR960006915A (ko) 췌장염의 치료 조성물